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Chronic Kidney Disease and
Cardiovascular Therapeutics
Time to Close the Evidence Gaps*
Tara I. Chang, MD, MS,
Glenn M. Chertow, MD, MPH
Palo Alto, California
National estimates suggest that more than 20 million adults
in the United States are affected by chronic kidney disease
(CKD), which is classified into 5 stages based on the
estimated glomerular filtration rate (GFR) or evidence of
kidney damage (Table 1) (1–3). Given the ubiquity of overt
and subclinical cardiovascular disease (CVD), it is not
surprising that the prevalence of concomitant CKD and
CVD is also very high, with upward of 40% of patients with
CKD also having CVD (4). CKD is well established as a
risk factor for cardiovascular events and death, with higher
See page 1152
event rates evident at progressively more advanced stages of
CKD (5,6). Assuming similar relative risk reductions for a
particular therapeutic agent, patients with CKD would have
larger absolute risk reductions than would patients without
CKD, translating to fewer patients who would need to be
treated to prevent a single event. However, patients with
CKD are often less likely to receive evidence-based thera-
pies such as aspirin, beta-blockers, antiplatelet agents, or
statins following an acute CVD event (7–9). The lower use
of therapies considered the standard of care might be driven
in part by fear of adverse side effects, coupled with uncer-
tainty regarding the relative efficacy of these therapies in
CKD. Are such concerns justified, or essentially a form of
bias (albeit, perhaps, unintentional) against patients with
CKD?
Currently there are few data available to answer this
important question, because most randomized clinical trials
(RCTs) in CVD systematically excluded patients with
CKD, did not report baseline creatinine or estimated GFR,
or did not conduct subgroup analyses in patients with CKD
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From the Division of Nephrology, Department of Medicine, Stanford University
School of Medicine, Palo Alto, California. The authors have reported that they have
no relationships relevant to the contents of this paper to disclose.(10). In this issue of the Journal, Badve et al. (11) highlight
the evidence and persistent evidence gaps related to the
efficacy and safety of pharmacotherapies in patients with
CKD in a well-conducted meta-analysis of beta-adrenergic
antagonists (“beta-blockers”). What is most striking about
the work of Badve et al. (11) is what they did not find:
espite a comprehensive search for RCTs that reported
ortality outcomes in patients with stage 3 or higher CKD,
nly 8 studies were suitable for inclusion. Two of these
tudies included data on beta-blockers in 977 patients with
KD without heart failure. Both trials compared a beta-
locker to a comparator drug rather than placebo and were
esigned to examine CKD progression as the primary
utcome, rather than CVD events or mortality. Ninety
ercent of patients came from AASK (African American
tudy of Kidney Disease and Hypertension), which ran-
omized patients with nonproteinuric CKD to receive
etoprolol, ramipril, or amlodipine. A previous post-hoc
nalysis of AASK (12) showed no significant effect of
etoprolol versus either of the other 2 agents on cardiovas-
ular outcomes. Given the very limited data, Badve et al.
11) did not attempt a quantitative meta-analysis and
ppropriately concluded that the evidence precluded any
efinitive comment on the efficacy of beta-blockers to
revent mortality and cardiovascular outcomes in patients
ith CKD without heart failure.
The investigators were able to be slightly more definitive
hen considering the effects of beta-blockers in patients
ith CKD and heart failure. They identified 6 placebo-
ontrolled trials conducted in 5,927 patients with systolic
eart failure (modest numbers when compared with another
ecent meta-analysis of beta-blocker use in heart failure,
onducted with a similar search strategy but not limited to
rials that included patients with CKD, which yielded 23
CTs conducted in 19,209 patients [13]). In pooled anal-
ses, Badve et al. (11) demonstrated that beta-blocker use
onferred a 28% (95% confidence interval [CI]: 20% to
6%) lower risk of all-cause mortality, and 34% (95% CI:
1% to 51%) lower risk of cardiovascular mortality in
atients with CKD and systolic heart failure. Based on trial
nclusion criteria, the majority of patients with CKD in
hese trials had stage 3a CKD; only about 10% of patients
ad an estimated GFR 30 ml/min/1.73 m2, and 2% were
on dialysis. Therefore, the robust beneficial effect of beta-
blockers demonstrated in placebo-controlled RCTs show-
ing no significant effect modification by CKD status pro-
vides convincing evidence to support their use in patients
with systolic heart failure and relatively mild CKD.
Whether clinicians should use beta-blockers to treat systolic
heart failure in patients with more advanced CKD remains
unclear, as is the question of whether beta-blockers should
be used in diastolic or mixed heart failure in this population.
Patients on maintenance dialysis are at very high risk of
cardiovascular events; mortality rates approach 20% per
year, with one-half of deaths attributed to CVD (14). Yet
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dialysis is even sparser than for patients with nondialysis-
requiring CKD. As noted, Badve et al. (11) found only a
single randomized trial of beta-blockers in patients on
hemodialysis, which demonstrated a significant survival
benefit of carvedilol versus placebo. However, with just 114
subjects enrolled, the power to demonstrate a modest-to-
large relative benefit was low, and the likelihood of false
positive results quite high. To date, only 2 RCTs of
renin-angiotensin-aldosterone system (RAAS) inhibitors
on cardiovascular outcomes and mortality have been con-
ducted in patients on dialysis (15,16). Therefore, clinicians
rely primarily on extrapolation of data from the general
population, a particularly problematic approach, because
patients on dialysis are vastly different from other patients.
For example, statins consistently reduce cardiovascular mor-
bidity and mortality in the general population, but 2 large
RCTs of statins in patients on hemodialysis showed no
benefit on cardiovascular outcomes or mortality (17,18).
What about the issue of safety of cardiovascular thera-
peutics in patients with CKD? Badve et al. (11) found that
rates of medication discontinuation were not significantly
higher in patients receiving beta-blockers, although they did
have higher rates of bradycardia and hypotension than did
patients receiving placebo. What is not clear from the report
is whether overall rates of adverse events were higher in
patients with CKD than in patients without CKD. Such
therapeutic uncertainties are not limited to beta-blockers, as
similar observations have been made for other medication
classes, particularly RAAS inhibitors. Most studies (9,19–21),
though not all (8,22), have shown underuse of RAAS
inhibitors for secondary prevention in patients with CKD,
which may be related to the fear of precipitating elevations
in serum creatinine and potassium. However, as with the
beta-blocker trials, most RAAS inhibitor trials excluded
patients with CKD stages 3b, 4, and 5, and fewer than 60%
of the major RAAS inhibitor trials even reported rates of
adverse renal effects (11). Therefore, although post hoc
analyses of RCTs using RAAS inhibitors in heart failure
have shown similar benefits in patients with mild to mod-
erate CKD as in patients with normal kidney function
(23,24), their efficacy and safety in more advanced CKD
Stages of CKDTable 1 Stages of CKD
Stage GFR (ml/min/1.73 m2) Description
1 90 Kidney damage with normal or increased GFR
2 60–89 Kidney damage with mild decrease in GFR
3a 45–59
Moderate decrease in GFR
3b 30–44
4 15–29 Severe decrease in GFR
5 15 or dialysis Kidney failure
Kidney damage defined as abnormal pathology, blood, urine, or imaging studies.
CKD  chronic kidney disease; GFR  glomerular filtration rate.remain unknown.In summary, less aggressive treatment of patients with
CKD and CVD cannot be justified based on the limited
available data. Badve et al. (11) underscore the large gaps in
evidence regarding management of CVD in patients with
CKD stages 3b and higher who are at the highest risk for
poor cardiovascular outcomes and death. Filling those gaps
will require relatively large trials focused exclusively on this
high risk population or inclusion of large subsets of patients
with stage 3b and higher CKD in other trials. Fortunately,
there are some indications that CVD trials are becoming
more inclusive of patients with advanced CKD. The re-
cently completed SHARP (Study of Heart and Renal
Protection) trial, which examined the effect of simvastatin
and ezetimibe versus placebo on major atherosclerotic
events, was conducted exclusively in patients with signifi-
cant CKD (mean estimated GFR: 27 ml/min/1.73 m2) or
on dialysis (25). The ongoing SPRINT (Systolic Blood
Pressure Intervention Trial) study will compare the effect of
2 different systolic blood pressure targets on incident CVD
events in a cohort in which 45% of participants will have an
estimated GFR between 25 and 59 ml/min/1.73 m2 (26).
ephrologists and cardiologists alike need evidence to
nform practice and improve outcomes for the millions of
atients worldwide with CKD and CVD. The time is now
or patients with all CKD stages, including patients on
ialysis, to take center stage in future cardiovascular trials.
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